Base de dados : MEDLINE
Pesquisa : D02.033.100.624.698.085 [Categoria DeCS]
Referências encontradas : 967 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 97 ir para página                         

  1 / 967 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29050562
[Au] Autor:Polhemus DJ; Trivedi RK; Gao J; Li Z; Scarborough AL; Goodchild TT; Varner KJ; Xia H; Smart FW; Kapusta DR; Lefer DJ
[Ad] Endereço:Cardiovascular Center of Excellence, Louisiana State University (LSU) Health Sciences Center, New Orleans, Louisiana; Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, Louisiana.
[Ti] Título:Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
[So] Source:J Am Coll Cardiol;70(17):2139-2153, 2017 Oct 24.
[Is] ISSN:1558-3597
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Sustained sympathetic activation contributes to the progression of myocardial cell injury, cardiac fibrosis, and left ventricular (LV) dysfunction in heart failure (HF). OBJECTIVES: This study investigated the effects of radiofrequency renal nerve denervation (RF-RDN) on the pathobiology of HF and the interaction between the renal sympathetic nerves and natriuretic peptide (NP) metabolism. METHODS: Spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY) were subjected to 45 min of coronary artery ligation and reperfusion for 12 weeks. At 4 weeks post-reperfusion, SHR and WKY underwent either bilateral RF-RDN or sham-RDN. RESULTS: Following RF-RDN in both strains, LV ejection fraction remained significantly above those levels in respective sham-RDN rats, and at the end of the 12-week study, rats in both strains had significantly reduced LV fibrosis and improved vascular function. RF-RDN therapy significantly improved vascular reactivity to endothelium-dependent and -independent vasodilators as well as vascular compliance in the setting of severe HF. Improvements in LV function were accompanied by significant elevations in circulating NP as compared to those associated with sham-RDN. Further investigation into the cause of increased circulating NP levels demonstrated that RF-RDN significantly inhibited renal neprilysin activity in SHR and WKY with HF. Likewise, chronic treatment with the beta antagonist bisoprolol inhibited renal neprilysin activity and increased circulation NP levels in WKY with HF. CONCLUSIONS: This study identifies a novel endogenous pathway by which the renal nerves participate in the degradation of cardioprotective NP. Furthermore, removal of the influence of the renal nerves on kidney function attenuates renal neprilysin activity, augments circulating NP levels, reduces myocardial fibrosis, and improves LV function in the setting of HF.
[Mh] Termos MeSH primário: Insuficiência Cardíaca/terapia
Rim/inervação
Neprilisina/antagonistas & inibidores
Simpatectomia
[Mh] Termos MeSH secundário: Aminobutiratos/farmacologia
Angiotensina II/sangue
Animais
Bisoprolol/farmacologia
Pressão Sanguínea
Ecocardiografia
Miocárdio/química
Miocárdio/patologia
Neprilisina/fisiologia
Nitritos/análise
Norepinefrina/sangue
Ratos
Ratos Endogâmicos SHR
Ratos Endogâmicos WKY
Artéria Renal/inervação
Renina/sangue
Traumatismo por Reperfusão/fisiopatologia
Tetrazóis/farmacologia
Função Ventricular Esquerda/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminobutyrates); 0 (LCZ 696); 0 (Nitrites); 0 (Tetrazoles); 11128-99-7 (Angiotensin II); EC 3.4.23.15 (Renin); EC 3.4.24.11 (Neprilysin); X4W3ENH1CV (Norepinephrine); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171021
[St] Status:MEDLINE


  2 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28732286
[Au] Autor:Malik P; Bhushan R
[Ad] Endereço:Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, 247667, India. Electronic address: pmalik2289@gmail.com.
[Ti] Título:Development of liquid chromatographic methods for enantioseparation and sensitive detection of ß-adrenolytics/ß2-agonists in human plasma using a single enantiomer reagent.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1061-1062:117-122, 2017 Sep 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Enantioseparation of four commonly used ß-adrenolytics (bisoprolol, salbutamol, and carvedilol, marketed as racemic mixtures) has been achieved by both TLC and RPHPLC via an indirect approach. A new chiral reagent, (S)-naproxen benzotriazole ester, was synthesized and it was characterized by UV, IR, HNMR, elemental analysis and polarimetry. It was used to synthesize diastereomeric derivatives of the three ß-adrenolytics under microwave irradiation. TLC separation of diastereomeric derivatives was achieved which were then isolated by preparative approach; these were characterized and were used as standard reference for determining absolute configuration of diastereomeric derivatives and for establishing validated HPLC method for enantioseparation and sensitive detection of the three ß-adrenolytics in human plasma. Mobile phase in gradient mode containing methanol and aqueous triethylaminephosphate (TEAP) was successful for HPLC separation; conditions with respect to pH, flow rate, and buffer concentration were optimized. The method is capable to accurately quantitate ß-adrenolytics in human plasma with minimal sample clean-up and rapid separation by TLC and RPHPLC. The limit of detection values were 0.97 and 0.87ng/mL for diastereomeric derivatives of (S)- and (R)-bisoprolol, respectively, which are very low in comparison to literature reports.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos beta 2/sangue
Agonistas de Receptores Adrenérgicos beta 2/isolamento & purificação
Antagonistas Adrenérgicos beta/sangue
Antagonistas Adrenérgicos beta/isolamento & purificação
Cromatografia Líquida de Alta Pressão/métodos
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos beta 2/química
Antagonistas Adrenérgicos beta/química
Albuterol/sangue
Albuterol/química
Albuterol/isolamento & purificação
Bisoprolol/sangue
Bisoprolol/química
Bisoprolol/isolamento & purificação
Carbazóis/sangue
Carbazóis/química
Carbazóis/isolamento & purificação
Seres Humanos
Limite de Detecção
Modelos Lineares
Naproxeno/química
Propanolaminas/sangue
Propanolaminas/química
Propanolaminas/isolamento & purificação
Reprodutibilidade dos Testes
Estereoisomerismo
Triazóis/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-2 Receptor Agonists); 0 (Adrenergic beta-Antagonists); 0 (Carbazoles); 0 (Propanolamines); 0 (Triazoles); 0K47UL67F2 (carvedilol); 57Y76R9ATQ (Naproxen); 86110UXM5Y (benzotriazole); QF8SVZ843E (Albuterol); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE


  3 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28649007
[Au] Autor:Powers JM; Murphy G; Ralph N; O'Gorman SM; Murphy JEJ
[Ad] Endereço:Mitochondrial Biology & Radiation Research Centre, Dept Life Sciences, IT Sligo, Sligo, Ireland. Electronic address: Julia.Powers@mail.itsligo.ie.
[Ti] Título:Polypharmacy and sun exposure: Implications for mitochondrial DNA deletions in skin.
[So] Source:J Photochem Photobiol B;173:397-403, 2017 Aug.
[Is] ISSN:1873-2682
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Most somatic cells contain many copies of mitochondrial DNA (mtDNA). Because of both the high copy number and the lack of repair mechanisms available to mtDNA, damage to it largely goes unrepaired, and can accumulate over time. Large scale deletions are a recognised type of damage sustained by mtDNA as a consequence of exposure to the ultraviolet light in sunlight. A group of patients were identified as having abnormally high levels of either a 4977 base pair deletion (mtDNA ) or 3895 base pair deletion (mtDNA ), in mtDNA from sun exposed skin or skin suspected to be a non-melanoma skin cancer, but not in their non-sun exposed skin biopsies. In three of the four cases, skin cancer was ruled out due to histological testing. Additional factors from these patients' medical histories were studied, and it was noted that they shared diagnoses for multiple pathologies common to an older population, and that they were being treated with the same or related pharmaceuticals, including some that had been known to cause dermal side effects. Investigation into the biochemistry underlying the symptoms, the effects of sun exposure and side effects of the prescribed pharmaceuticals revealed a possible synergistic relationship leading to the localised high levels of mtDNA deletions.
[Mh] Termos MeSH primário: DNA Mitocondrial/genética
Mitocôndrias/efeitos da radiação
Pele/efeitos da radiação
Raios Ultravioleta
[Mh] Termos MeSH secundário: Idoso
Alopurinol/farmacologia
Atorvastatina Cálcica/farmacologia
Bisoprolol/farmacologia
Colesterol/química
Dano ao DNA/efeitos dos fármacos
Dano ao DNA/efeitos da radiação
DNA Mitocondrial/metabolismo
Deleção de Genes
Seres Humanos
Mitocôndrias/efeitos dos fármacos
Mitocôndrias/genética
Perindopril/farmacologia
Pravastatina/farmacologia
Reação em Cadeia da Polimerase em Tempo Real
Pele/efeitos dos fármacos
Pele/patologia
Ubiquinona/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Mitochondrial); 1339-63-5 (Ubiquinone); 48A5M73Z4Q (Atorvastatin Calcium); 63CZ7GJN5I (Allopurinol); 97C5T2UQ7J (Cholesterol); KXO2KT9N0G (Pravastatin); Y41JS2NL6U (Bisoprolol); Y5GMK36KGY (Perindopril)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE


  4 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28364270
[Au] Autor:Meattini I; Curigliano G; Terziani F; Becherini C; Airoldi M; Allegrini G; Amoroso D; Barni S; Bengala C; Guarneri V; Marchetti P; Martella F; Piovano P; Vannini A; Desideri I; Tarquini R; Galanti G; Barletta G; Livi L
[Ad] Endereço:Azienda Ospedaliero Universitaria Careggi - University of Florence, Largo G.A. Brambilla 3, 50134, Florence, Italy. icro.meattini@unifi.it.
[Ti] Título:SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
[So] Source:Med Oncol;34(5):75, 2017 May.
[Is] ISSN:1559-131X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Over the years, thanks to the addition of new generation systemic agents, as well as the use of more advanced and precise radiotherapy techniques, it was able to obtain a high curability rate for breast cancer. Anthracyclines play a key role in the treatment of breast disease, with a well-known benefit on disease-free survival of patients with positive nodal status. Trastuzumab have shown a significant outcome advantage after 1-year administration in case of HER2-positive disease. Unfortunately, significant increase in cardiotoxicity has been observed after anthracyclines and trastuzumab therapies. Even though the cardiology and oncology community strongly recommend a cardiotoxicity prevention strategy for this subset of patients, there is still no consensus on the optimal patient's approach. We aimed to review the published and ongoing researches on cardioprevention strategies and to present the SAFE trial (CT registry ID: NCT2236806; EudraCT number: 2015-000914-23). It is a randomized phase 3, four-arm, single-blind, placebo-controlled study that aims to evaluate the effect of bisoprolol, ramipril or both drugs, compared to placebo, on subclinical heart damage evaluated by speckle tracking cardiac ultrasound in non-metastatic breast cancer patients.
[Mh] Termos MeSH primário: Antraciclinas/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Neoplasias da Mama/tratamento farmacológico
Cardiotônicos/uso terapêutico
Cardiotoxicidade/prevenção & controle
Trastuzumab/efeitos adversos
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Bisoprolol/uso terapêutico
Ensaios Clínicos Fase III como Assunto
Feminino
Seres Humanos
Ramipril/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Trastuzumab/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anthracyclines); 0 (Cardiotonic Agents); L35JN3I7SJ (Ramipril); P188ANX8CK (Trastuzumab); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170402
[St] Status:MEDLINE
[do] DOI:10.1007/s12032-017-0938-x


  5 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27893331
[Au] Autor:Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
[Ad] Endereço:Edith Pituskin John R. Mackey, Sheri Koshman, Mark J. Haykowsky, Joseph J. Pagano, Kelvin Chow, Richard B. Thompson, Larissa J. Vos, Sunita Ghosh, Gavin Y. Oudit, Justin A. Ezekowitz, and D. Ian Paterson, University of Alberta, Edmonton, Alberta; and Davinder Jassal and Marshall Pitz, University of
[Ti] Título:Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
[So] Source:J Clin Oncol;35(8):870-877, 2017 Mar 10.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose The primary toxicity of trastuzumab therapy for human epidermal growth factor receptor 2-overexpressing (HER2-positive) breast cancer is dose-independent cardiac dysfunction. Angiotensin-converting enzyme inhibitors and ß-blockers are recommended first-line agents for heart failure. We hypothesized that angiotensin-converting enzyme inhibitors and ß-blockers could prevent trastuzumab-related cardiotoxicity. Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer were randomly assigned to receive treatment with perindopril, bisoprolol, or placebo (1:1:1) for the duration of trastuzumab adjuvant therapy. Patients underwent cardiac magnetic resonance imaging at baseline and post-cycle 17 for the determination of left ventricular volumes and left ventricular ejection fraction (LVEF). Cardiotoxicity was evaluated as the change in indexed left ventricular end diastolic volume and LVEF. Results Thirty-three patients received perindopril, 31 received bisoprolol, and 30 received placebo. Baseline demographic, cancer, and cardiovascular profiles were similar between groups. Study drugs were well tolerated with no serious adverse events. After 17 cycles of trastuzumab, indexed left ventricular end diastolic volume increased in patients treated with perindopril (+7 ± 14 mL/m ), bisoprolol (+8 mL ± 9 mL/m ), and placebo (+4 ± 11 mL/m ; P = .36). In secondary analyses, trastuzumab-mediated decline in LVEF was attenuated in bisoprolol-treated patients (-1 ± 5%) relative to the perindopril (-3 ± 4%) and placebo (-5 ± 5%) groups ( P = .001). Perindopril and bisoprolol use were independent predictors of maintained LVEF on multivariable analysis. Conclusion Perindopril and bisoprolol were well tolerated in patients with HER2-positive early breast cancer who received trastuzumab and protected against cancer therapy-related declines in LVEF; however, trastuzumab-mediated left ventricular remodeling-the primary outcome-was not prevented by these pharmacotherapies.
[Mh] Termos MeSH primário: Cardiotoxicidade/etiologia
Cardiotoxicidade/prevenção & controle
Trastuzumab/efeitos adversos
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos beta 1/uso terapêutico
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Bisoprolol/uso terapêutico
Neoplasias da Mama/tratamento farmacológico
Neoplasias da Mama/enzimologia
Cardiotoxicidade/diagnóstico por imagem
Método Duplo-Cego
Feminino
Seres Humanos
Imagem por Ressonância Magnética
Meia-Idade
Perindopril/uso terapêutico
Receptor ErbB-2
Volume Sistólico/efeitos dos fármacos
Trastuzumab/administração & dosagem
Remodelação Ventricular/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-1 Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); P188ANX8CK (Trastuzumab); Y41JS2NL6U (Bisoprolol); Y5GMK36KGY (Perindopril)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170802
[Lr] Data última revisão:
170802
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161129
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2016.68.7830


  6 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27859924
[Au] Autor:Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
[Ad] Endereço:Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
[Ti] Título:Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
[So] Source:Pharmacoepidemiol Drug Saf;26(1):81-90, 2017 Jan.
[Is] ISSN:1099-1557
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The long-term use of ß-blockers has been shown to improve clinical outcomes among patients with heart failure (HF). However, a lack of data persists in assessing whether carvedilol or bisoprolol are superior to metoprolol tartrate in clinical practice. We endeavored to compare the effectiveness of ß-blockers among older adults following a primary hospital admission for HF. METHODS: We conducted a cohort study using Quebec administrative databases to identify patients who were using ß-blockers, carvedilol, bisoprolol, or metoprolol tartrate after the diagnosis of HF. We characterized the patients by the type of ß-blocker prescribed at discharge of their first HF hospitalization. An adjusted multivariate Cox proportional hazards model was used to compare the primary outcome of all-cause mortality. We also conducted analyses by matching for a propensity score for initiation of ß-blocker therapy and assessed the effect on primary outcome. RESULTS: Among 3197 patients with HF with a median follow-up of 2.8 years, the crude annual mortality rates (per 100 person-years) were at 16, 14.9, and 17.7 for metoprolol tartrate, carvedilol, and bisoprolol, respectively. Adjusted hazard ratios of carvedilol (hazard ratio 0.92; 0.78-1.09) and bisoprolol (hazard ratio 1.04; 0.93-1.16) were not significantly different from that of metoprolol tartrate in improving survival. After matching for propensity score, carvedilol and bisoprolol showed no additional benefit with respect to all-cause mortality compared with metoprolol tartrate. CONCLUSIONS: Our evidence suggests no differential effect of ß-blockers on all-cause mortality among older adults with HF. Copyright © 2016 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Bisoprolol/uso terapêutico
Carbazóis/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
Metoprolol/uso terapêutico
Propanolaminas/uso terapêutico
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/uso terapêutico
Idoso
Estudos de Coortes
Bases de Dados Factuais
Feminino
Seguimentos
Insuficiência Cardíaca/mortalidade
Hospitalização
Seres Humanos
Masculino
Pontuação de Propensão
Modelos de Riscos Proporcionais
Quebeque
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Carbazoles); 0 (Propanolamines); 0K47UL67F2 (carvedilol); GEB06NHM23 (Metoprolol); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE
[do] DOI:10.1002/pds.4132


  7 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27792991
[Au] Autor:Toyoda S; Haruyama A; Inami S; Amano H; Arikawa T; Sakuma M; Abe S; Tanaka A; Node K; Inoue T
[Ad] Endereço:Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan. Electronic address: s-toyoda@dokkyomed.ac.jp.
[Ti] Título:Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure.
[So] Source:Int J Cardiol;226:71-76, 2017 Jan 01.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study was designed to elucidate differences in effects of 2 beta blockers, bisoprolol and carvedilol, in patients with chronic heart failure. BACKGROUND: Although the beta blockers bisoprolol and carvedilol are commonly used in patients with chronic heart failure, differences in the efficacy and safety of these medications have not been established in this patient population. METHODS: Patients with chronic systolic heart failure, defined as ≤45% ejection fraction, who had received intensive medical therapy with the exception of beta blockers, were randomly assigned to receive either bisoprolol or carvedilol for 24weeks. RESULTS: A total of 67 patients were enrolled in the study (bisoprolol: 38 patients, carvedilol: 29 patients). No difference was observed in the improvement of NYHA class, ejection fraction, or N-terminal pro-brain-type natriuretic peptide level between groups. In contrast, the level of high sensitivity troponin T decreased in the bisoprolol group [-4.1±0.9 to -4.5±0.8 log (ng/ml), P=0.003], but did not change in the carvedilol group [-4.4±1.1 to -4.6±0.8 log (ng/ml), P=0.161]. Forced expiratory volume in the first second increased in the bisoprolol group [2.26±0.70 to 2.40±0.70 (L), P=0.014], but did not change in the carvedilol group [2.53±0.71 to 2.59±0.78 (L), P=0.127]. CONCLUSION: Bisoprolol might be superior to carvedilol in providing protection from myocardial injury and preserving pulmonary function in patients with chronic systolic heart failure.
[Mh] Termos MeSH primário: Antagonistas de Receptores Adrenérgicos beta 1/administração & dosagem
Bisoprolol/administração & dosagem
Cardiotônicos/administração & dosagem
Volume Expiratório Forçado/efeitos dos fármacos
Insuficiência Cardíaca/tratamento farmacológico
Insuficiência Cardíaca/fisiopatologia
[Mh] Termos MeSH secundário: Idoso
Doença Crônica
Feminino
Seguimentos
Volume Expiratório Forçado/fisiologia
Insuficiência Cardíaca/sangue
Seres Humanos
Masculino
Meia-Idade
Testes de Função Respiratória/métodos
Resultado do Tratamento
Troponina T/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic beta-1 Receptor Antagonists); 0 (Cardiotonic Agents); 0 (Troponin T); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161030
[St] Status:MEDLINE


  8 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27534738
[Au] Autor:Yang T; Jiang Y; Hao Y; Zhou S; Xu X; Qu B; Lin X; Ma T
[Ad] Endereço:Cardiovascular Department, Xiangya Hospital, Central South University, Changsha, China.
[Ti] Título:Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study.
[So] Source:Hypertens Res;40(1):79-86, 2017 Jan.
[Is] ISSN:1348-4214
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This open-label study investigated the long action of bisoprolol compared with metoprolol CR/ZOK for controlling the mean dynamic heart rate (HR) and blood pressure (BP) in patients with mild-to-moderate primary hypertension. Patients from seven centers in China were treated with either bisoprolol 5 mg or metoprolol CR/ZOK 47.5 mg once daily for 12 weeks. The primary end points were the mean dynamic HR reduction and the mean dynamic diastolic BP (DBP) control in the last 4 h of the treatment period. Secondary end points included ambulatory monitoring of the BP and HR, safety and compliance. A total of 186 patients, with 93 patients in each group, were enrolled and analyzed. In the last 4 h of the treatment period, patients receiving bisoprolol demonstrated a significantly greater reduction in the mean dynamic HR compared with patients receiving metoprolol CR/ZOK (least squares means (LSmeans) of difference: -3.79 b.p.m.; 97.5% confidence interval (CI): -7.45, -0.14; P=0.0202). Furthermore, in the last 4 h of the treatment period, bisoprolol demonstrated non-inferiority vs. metoprolol CR/ZOK in lowering the mean dynamic DBP (LSmeans of difference: -1.00; 97.5% CI: -4.79, 2.78; P=0.5495). Bisoprolol further significantly lowered the 24-h mean ambulatory, mean daytime and mean nighttime HR. The overall adverse event rate was similar between the two groups. Noncompliance was reported in 3 (3.53%) and 6 (7.32%) patients in the bisoprolol and metoprolol CR/ZOK groups, respectively. In conclusion, bisoprolol provided superior dynamic HR reduction and non-inferior dynamic BP reduction vs. metoprolol CR/ZOK in patients with mild-to-moderate hypertension. No new safety concerns were found.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Bisoprolol/uso terapêutico
Pressão Sanguínea/efeitos dos fármacos
Frequência Cardíaca/efeitos dos fármacos
Hipertensão/tratamento farmacológico
Metoprolol/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Anti-Hipertensivos/farmacologia
Bisoprolol/farmacologia
Monitorização Ambulatorial da Pressão Arterial
Preparações de Ação Retardada
Feminino
Seres Humanos
Masculino
Metoprolol/farmacologia
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Delayed-Action Preparations); GEB06NHM23 (Metoprolol); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160819
[St] Status:MEDLINE
[do] DOI:10.1038/hr.2016.101


  9 / 967 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27391910
[Au] Autor:Bus-Kwasnik K; Rudzki PJ; Ksycinska H; Les A; Serafin-Byczak K; Raszek J; Bielak A; Wybraniec A; Platek AE; Szymanski FM; Lazowski T
[Ti] Título:Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers.
[So] Source:Kardiol Pol;75(1):48-54, 2017.
[Is] ISSN:1897-4279
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bisoprolol is one of the most widely used beta-blockers characterised by cardioselectivity, and it has no intrinsic sympathomimetic activity. It is commonly used in the treatment of coronary heart disease and heart failure. AIM: The aim of study was to assess the bioequivalence of the film-coated tablets containing 2.5 mg of bisoprolol (Bisocard® - the medicinal product) to the original medicinal product (Concor Cor 2.5® - the reference). METHODS: A randomised, open-label, two-period, crossover, single-dose, relative bioavailability study was conducted in fasted healthy Caucasian volunteers. A single 10-mg oral dose (four tablets of 2.5 mg) of the test or reference product was followed by a 14-day wash-out period, after which the subjects received the alternative product. Blood was sampled within a period of 60 h post administration in pre-specified time points. Bisoprolol concentrations were determined by a validated LC-MS/MS method. The products were considered bioequivalent if the 90% confidence interval (CI) of the log-transformed geometric mean ratios (test vs. reference) for AUC(0-t), AUC(0-∞), and Cmax were within 80-125% limits. Adverse events were monitored during the study based on the subject claims and clinical parameters. RESULTS: Twenty-six healthy male and female volunteers (mean age ca. 29 years; body mass index 22.7 kg/m²) were in-cluded in the study, and 24 completed the clinical part. The geometric mean ratios (test/reference) for the log-transformed AUC(0-t), AUC(0-∞), and Cmax were 95.16% (90% CI 92.52-97.87%), 95.08% (90% CI 92.40-97.83%), and 100.00% (90% CI 94.83-105.45%), respectively. There were no significant differences in the pharmacokinetic parameters between the test and reference formulations. No serious adverse events were reported. CONCLUSIONS: The results of this single-dose study in healthy Caucasian volunteers indicate that Bisocard®; 2.5 mg film-coated tablets are bioequivalent to the reference product - Concor Cor 2.5®; 2.5 mg film-coated tablets. Both products had similar safety profile and have been well tolerated.
[Mh] Termos MeSH primário: Bisoprolol/farmacocinética
Comprimidos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Disponibilidade Biológica
Bisoprolol/administração & dosagem
Bisoprolol/sangue
Bisoprolol/uso terapêutico
Cromatografia Líquida
Doença das Coronárias/tratamento farmacológico
Estudos Cross-Over
Composição de Medicamentos
Grupo com Ancestrais do Continente Europeu
Feminino
Insuficiência Cardíaca/tratamento farmacológico
Seres Humanos
Masculino
Meia-Idade
Espectrometria de Massas em Tandem
Equivalência Terapêutica
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tablets); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160709
[St] Status:MEDLINE
[do] DOI:10.5603/KP.a2016.0106


  10 / 967 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28294867
[Au] Autor:Tarlovskaya EI; Chudinovskih TI
[Ad] Endereço:1Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia: 2Kirov State Medical Academy Kirov, Russia.
[Ti] Título:[Comparative Prospective Clinical Economic Study of Original and Generic Bisoprolol in Patients With Coronary Heart Disease].
[So] Source:Kardiologiia;56(5):12-17, 2016 May.
[Is] ISSN:0022-9040
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:PURPOSE: to conduct comparative clinical and economical analysis of original and generic preparations of bisoprolol. MATERIALS AND METHODS: The study included 61 patients after acute coronary syndrome (ACS) (34 men, 27 women, age 46-78 years). Patients were distributed (envelope method) to 2 groups. Patients of group A received original bisoprolol, of group C - generic drug. Duration of observation was 6 weeks. Parameters analyzed were dynamics of heart rate (HR), data of treadmill exercise test, and values of calculated cost/effectiveness ratio. RESULTS: In both groups we observed significant slowing of HR. Data of treadmill test showed similar increases of volume of work.
[Mh] Termos MeSH primário: Doença das Coronárias
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta
Idoso
Bisoprolol
Teste de Esforço
Feminino
Frequência Cardíaca
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); Y41JS2NL6U (Bisoprolol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE



página 1 de 97 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde